AstraZeneca (MEX:AZNN) Total Receivables: MXN254,369 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AZNN AstraZeneca PLC MEX:AZNN
88 GF Score
Price MXN1,628.00
GF Value MXN1,703.98
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Total Receivables?

AstraZeneca MEX:AZNN +1.25% 88 Total Receivables is MXN254,369 Mil as of Mar. 2026. GuruFocus rates MEX:AZNN with a GF Score™ of 88/100 and a GF Value™ of MXN1,703.98. The stock has 1 warning sign investors should review.

AstraZeneca's Total Receivables for the quarter that ended in Mar. 2026 was MXN254,369 Mil.

AstraZeneca Total Receivables Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Total Receivables Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 166,819.85 179,207.23 178,382.37 234,313.79 236,648.92

AstraZeneca Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 271,071.15 266,772.11 263,019.14 236,648.92 254,369.27
MEX:AZNN
88GF Score
AstraZeneca PLC MEX:AZNN
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of MXN254,369 Mil mean?
AstraZeneca (MEX:AZNN) has a Total Receivables of MXN254,369 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's Total Receivables too high?
AstraZeneca's current Total Receivables is MXN254,369 Mil. Overall, AstraZeneca has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Total Receivables compare to LLY and JNJ?
AstraZeneca's Total Receivables of MXN254,369 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on AstraZeneca and its competitors. AstraZeneca's current Total Receivables is MXN254,369 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
AstraZeneca (MEX:AZNN) has a current Total Receivables of MXN254,369 Mil. The stock's GF Value™ is MXN1,703.98, compared to a current price of MXN1,628.00 — trading 4.5% below its estimated fair value. The current Total Receivables is MXN254,369 Mil. AstraZeneca's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For AstraZeneca (MEX:AZNN), the current Total Receivables is MXN254,369 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (MEX:AZNN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of MXN1,628.00 is trading 4.5% below its estimated GF Value™ of MXN1,703.98.

Key valuation signals for MEX:AZNN:

  • Total Receivables: MXN254,369 Mil
  • GF Value™: MXN1,703.98 vs. price of MXN1,628.00 (4.5% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the MEX:AZNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for MEX:AZNN

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,628.00
Price
MXN1,703.98
GF Value